Assessment of the blood–brain barrier in CNS drug discovery
Authors:
- Phil JeffreyPJPhil Jeffrey
- Scott SummerfieldSSScott Summerfield
- 1 January 2010
- journal article
- review article
- Published by Elsevier in Neurobiology of Disease
- Vol. 37 (1) , 33-37
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial FluidDrug Metabolism and Disposition, 2009
- Strategies to assess blood–brain barrier penetrationExpert Opinion on Drug Discovery, 2008
- Multiplicity of cerebrospinal fluid functions: New challenges in health and diseaseFluids and Barriers of the CNS, 2008
- LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood–brain barrier in vitro modelNeurobiology of Disease, 2008
- Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and MorphineAnesthesiology, 2008
- On The Rate and Extent of Drug Delivery to the BrainPharmaceutical Research, 2007
- Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modelingThe AAPS Journal, 2005
- Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamicsAdvanced Drug Delivery Reviews, 2004
- How significant is the role of P-glycoprotein in drug absorption and brain uptake?Drugs of Today, 2004
- Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical SettingClinical Pharmacokinetics, 2002